Director Share Purchases

RNS Number : 5400D

ReNeuron Group plc

30 January 2015

 



30 January 2015

AIM: RENE

ReNeuron Group plc

("ReNeuron" or "the Company")

        Director Share Purchases

Guildford, UK, 30 January 2015: ReNeuron Group plc (AIM: RENE), a leading UK-based stem cell therapy company, was informed on 29 January 2015 that two of its Directors acquired ordinary shares of 1p each ("Ordinary Shares") as follows:

				Interest after purchase
Director	Title	Number of Ordinary Shares acquired on 29 January 2015	Price  per share	Number of Ordinary Shares	% of total issued share capital
Olav Hellebø	Chief Executive Officer	322,778	3.1p	322,778	0.02%
Michael Hunt	Chief Financial Officer	161,556	3.1p	1,508,471	0.08%

The issued share capital of the Company is 1,788,827,700 1p ordinary shares.

Enquiries:

ReNeuron	[phone]
Olav Hellebø, Chief Executive Officer Michael Hunt, Chief Financial Officer
Buchanan	[phone]
Mark Court, Sophie Cowles, Stephanie Watson
Cenkos Securities	[phone]
Stephen Keys, Dr Christopher Golden (NOMAD and Broker)
Andy Roberts (Sales)

About ReNeuron

ReNeuron is a leading, clinical-stage cell therapy development business.  Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.  

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments.  The Company's therapeutic candidates for stroke disability and critical limb ischaemia are in clinical development and its cell-based treatment for blindness-causing diseases of the retina is currently in pre-clinical development. 

ReNeuron is also advancing a proprietary platform technology to exploit nanoparticles (exosomes) secreted by stem cells as potential new drug candidates targeting indications in tissue repair, fibrosis and cancer.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  Further information on ReNeuron and its products can be found at www.reneuron.com.

 

END

 

 

RDSPKCDBABKDDDB